Otilimab Failure Is A Blow For GSK’s Pipeline, With More Tests To Come
Arthritis Drug Was Blockbuster Candidate
GSK is abandoning one of its new drug prospects after it failed in hard-to-treat rheumatoid arthritis patients at Phase III, raising the stakes for more key readouts due shortly.
